This study investigates cancer with BRAF alterations. It focuses on participants with either solid tumors or primary central nervous system (CNS) tumors that have specific changes in the BRAF gene.
The study evaluates how safe and effective the investigational medication is for these cancer conditions. It examines the overall impact on health and any potential side effects.
- Who can participate: Participants must be 10 years or older, weigh at least 30 kg, and have a diagnosis of a solid tumor or CNS tumor with BRAF alterations after prior standard therapies.
- Study details: Participants will take the investigational medication and may also receive a placebo, an inactive substance that looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand